Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: Results from a multinational, placebo-controlled study

Diabetes Research and Clinical Practice

Volumn 60, Issue 2, 2003, Pages 111-118

  Hwu, Chii Min ^a   Ho, Low Tone ^a   Fuh, Martin M T ^b   Siu, Shing Chung ^c   Sutanegara, Dwi ^d   Piliang, Sjafii ^e   Chan, Juliana C N ^f  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c TUNG WAH EASTERN HOSPITAL   (Hong Kong)

^d Department of Internal Medicine   (Indonesia)

^e Pirngadi Teaching Hospital   (Indonesia)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Acarbose; Asian; Glycemic control; Insulin; Type 2 diabetes

Indexed keywords

ACARBOSE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037404140     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(03)00015-9     Document Type: Article

References (18)

1. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 15:1992;318-368.
2. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetic Study (UKPDS) Group. JAMA. 281:1999;2005-2012.
3. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 24:2001;758-767.
4. Clissold S.P., Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 35:1988;214-243.
5. Buse J.B. The use of insulin alone and in combination with oral agents in type 2 diabetes. Primary Care. 26:1999;931-950.
6. Chiasson J.-L., Josse R.G., Hunt J.A., et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann. Intern. Med. 121:1994;928-935.
7. Coniff R.F., Shapira J.A., Seaton T.B., Hoogwerf B.J., Hunt J.A. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care. 18:1995;928-932.
8. Kelley D.E., Bidot P., Freedman Z., et al. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care. 21:1998;2056-2061.
9. Coniff R.F., Shapiro J.A., Seaton T.B., Bray G.A. Multicenter, placebo-controlled trial comparing acarbose (Bay g 5421) with placebo, tolbutamide, and tobutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am. J. Med. 98:1995;443-451.
10. Wolever T.M.S., Chiasson J-L., Josse R.G., et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int. J. Obesity. 21:1997;756-763.
11. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes Res. Clin. Pr. 52:2001;193-204.
12. Chan J.C.N., Chan K.W.A., Ho L.L.T., et al. An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Diabetes Care. 21:1998;1058-1061.
13. Lam K.S.L., Tiu S.C., Tsang M.W., Ip T.P., Tam S.C.F. Acarbose in NIDDM patients with poor control on conventional oral agents. Diabetes Care. 21:1998;1154-1158.
14. Henry R.R., Gumbiner B., Ditzler T., Wallace P., Lyon R., Glauber H.S. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care. 16:1993;21-31.
15. Jenkins D.J.A., Taylor R.H., Goff D.V., et al. Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes. 30:1981;951-954.
16. Royall D., Wolever T.M., Jeejeebhoy K.N. Clinical significance of colonic fermentation. Am. J. Gastroenterol. 85:1990;1307-1312.
17. Holman R.R., Cull C.A., Turner R.C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care. 22:1999;960-964.
18. Kado S., Murakami T., Aoki A., et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res. Clin. Pr. 41:1998;49-55.